Fresh off a big earnings beat that we reported here , SeaGen is continuing to expand its applications for Hodgkins Lymphoma into Canada into other treatment platforms.
Seattle Genetics Announces Progress in Expanding ADCETRIS® (Brentuximab Vedotin) Indications in Canada
This is very similar to what we saw in their financial report, and what is happening in the US. But with expansion into Canada, this has two major effects:
1) Increased patient population will increase sales
2) Further demonstration of the indication expansion path to broaden the population even further from here.
No comments:
Post a Comment